48 results about "Multi drug resistant bacteria" patented technology

The invention discloses a novel compound 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin with a strong antibacterial effect which is optimized by transforming the structure of bishydroxycoumarin compounds, and provides a preparation method thereof, wherein the chemical structure and crystal structure are obtained. The novel compound 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin has an antibacterial application value in preparation of a medicine resisting staphylococcus aureus (ATCC29213), methicillin-resistant staphylococcus aureus (MRSA, XJ7502), USA300 (LAC) and vancomycin-resistant staphylococcus aureus (Mu20ATCC700699).

The present invention relates to compounds of the formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:

The invention belongs to the field of pharmaceutical chemistry, and discloses pleuromutilin derivatives having alkaline side chains and a preparation method thereof. The structural formula of the pleuromutilin derivatives having alkaline side chains is shown in Formula (I), wherein R is phenylpropylamine, phenylethylamine, 4-hydroxyl-phenylethylamine, 4-methylphenylethylamine, 2-methylphenylethylamine, 4-(2-aminoethyl)pyridine, di-iso-butylmanice, thiophene-2-ethylamine, octylamine, laurylamine, cetylamine, 2-(mesyl)ethylamine or 2-(methylthio)ethylamine. The derivatives have favorable activity of inhibiting drug-resistant Staphylococcus aureus and mycoplasma, and are especially suitable to serve as a novel antibacterial drug for preventing and treating human or animal infectious diseases caused by methicillin-resistant Staphylococcus aureus or multi-drug resistant bacteria.

The present invention provides methods of inhibiting the growth of Mycobacterium species or treating an animal having a Mycobacterium infection (including multi-drug resistance strains and extensively drug resistant strains) by administering a compound of the invention, a salt thereof, or a composition comprising the same.

The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and / or anaerobic Gram positive and / or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H. influenza, Moraxella, acid-fast organisms such as Mycobacterium tuberculosis as well as Linezolid resistant species of Staphylococcus and Enterococcus.

The present disclosure provides dry powder antibiotic compositions that are effective in the treatment of bacterial infections and associated conditions. Moreover, the present disclosure provides dry powder antibiotic compositions for the treatment of bacterial infections, by multi-drug resistant bacteria, resulting in the subsequent reduction in the prevalent rates of drug resistance.

The invention discloses a synthetic method of QseC ligand derivatives capable of inhibiting bacterial virulence and an application. The QseC ligand derivatives are bacterial membrane surface protein QseC ligands and can be specifically combined with the QseC ligands and be used for retroregulation of a qseC-qseB-fliC-flhD gene pathway, thereby inhibiting the release of bacterial pathogenic virulence factors, reducing the bacterial virulence and the invasiveness during the bacterial infection and further achieving the role of controlling the harm of the bacterial infection; however, the QseC ligand derivatives do not affect normal growth and reproduction of bacteria, thereby avoiding the initiation of bacterial drug resistance pressure. The QseC ligand derivatives have the advantages of good anti-bacterial effect, low toxicity, good stability and difficult drug resistance. The QseC ligand derivatives synthesized by the optimized synthetic method of the QseC ligands and the chemical synthetic method of the derivatives thereof can be used for preparing novel broad-spectrum antibacterial drugs with resistance to multi-drug-resistant bacteria infection.

The invention belongs to the field of medicinal chemistry, and particularly relates to a pleuromutilin derivative with 2-aminothiophenol and a 1,2,3-triazole side chain, preparation and application. The pleuromutilin derivative with 2-aminothiophenol and the 1,2,3-triazole side chain is a compound of a formula 2 or a pharmaceutically acceptable salt of the compound, and a solvent compound, an enantiomer, a diastereomer and a tautomer of the compound of the formula 2 or the pharmaceutically acceptable salt of the compound or a mixture of the compound of the formula 2 or the pharmaceutically acceptable salt of the compound in any ratio, and includes a racemic mixture, and the compound has good inhibition to methicillin-resistant staphylococcus aureus activity, and is especially suitable forbeing used as a novel antibacterial drug for prevention and treatment of infectious diseases caused by human or animals or methicillin-resistant staphylococcus aureus or multi-drug resistant bacteria.(Please see the specification for the formula).

The invention belongs to the technical field of medical materials and particularly relates to an organic / inorganic combined antibacterial composition and a preparation method and application thereof.The organic / inorganic combined antibacterial composition comprises nano-copper, tigecycline and polydopamine; the compound of inorganic antibacterial agent nanometer copper and organic antibiotic tigecycline is wrapped by polydopamine to produce the produce. The results show that the product has good resistance to multi-drug resistant bacteria and is attached to the surface of a catheter after air drying and filming, slow release of the antibacterial agent is achieved, and technical shortcomings that single antibactic has poor antibacterial effect, low antibacterial duration and easy sheddingof spraying composite films.

The invention provides antibacterial gold nanoparticles modified by tetrazole or derivatives thereof, and a preparation method and an application thereof. A substituted tetrazole part without antibacterial activity is connected with non-substituted gold nanoparticles without antibacterial activity, and the antibacterial gold nanoparticles are firstly applied in the antibacterial field; the obtained gold nanoparticles modified with substituted tetrazole have unexpected antibacterial effect. The synthesized gold nanoparticles have good antibacterial effect on both gram-negative bacteria and gram-positive bacteria, have broad antibacterial spectrum and can resist clinically isolated multi-drug resistant bacteria. Compared with the prior art, the gold nanoparticles are connected with mercapto-tetrazole compounds, the synthetic method adopts one-step synthesis in an aqueous phase, and the raw materials used in the synthesis are green and environmentally friendly.

Fulvic acid as the active ingredient is used in the treatment or inhibition of mutti-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended- spectrum beta-lactamase (ES8L) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, Klebsiella pneumoniae or Escherichia coli.. The fuivic acid can be provided in combination with one or more antibiotics from the class of carbapenems or polymyxin antibiotics.

The invention discloses a compound YT-011 resisting multi-drug resistant bacteria and a preparation method thereof. The compound YT-011 has an important supporting effect on the discovery of drugs resisting drug resistant bacteria based on a pathogenic mechanism. A technology for preparing an antibacterial active substance having a novel structure through a structure-modified microorganism-derived active mother nucleus is used as a key technology. The compound YT-011 provides a feasible method for the discovery of the innovative drug. The microorganism-derived physiological active substance having structural diversity increases the discovery ways of innovative drugs, and enriches the research and development ideas.

The invention discloses an external traditional Chinese medicinal lotion for treating infective wound caused by multi-drug resistant bacteria. In accordance with the pathogenesis of multi-drug resistant infective wound, the external lotion disclosed by the invention is prepared from the following traditional Chinese medicines which are capable of promoting blood circulation and removing stasis, clearing away heat and eliminating dampness, removing necrotic tissue and promoting generation of new tissue: thymifolious euphorbia herb, fortune silene herb with root, commen bomhax flower, root or bark of gluey litse, ophiorrhiza japonica, Japanese conehead herb, common squill bulb, circaeashape loosestrife herb and nipponian greenbrier rhizome and root. Upon clinical tests, total effective rate is 95%; and the external lotion is free from cross infection and is significant in curative effect.

Disclosed is pollution-free functional water with deodorization activity and sterilization activity against multi-drug resistant bacteria. In the present invention, the functional water is prepared by treating a solution which contains mixture of pulverized molasses, soybean and bamboo through decomposition tank, a first precipitation tank, a bio-tank, a second precipitation tank and filter. Also, disclosed in a method for preparing the functional water.

Novel benzoxazine oxazolidinone compounds, preparation methods and uses thereof are disclosed, which belong to the field of pharmacy. More specifically, novel benzoxazine oxazolidinone compounds represented by the following general formula (I), preparation methods and uses thereof in preparing medicament for treating infectious diseases, especially infectious diseases caused by multi-drug resistant bacteria, are disclosed.

Novel benzoxazine oxazolidinone compounds, preparation methods and uses thereof are disclosed, which belong to the field of pharmacy. More specifically, novel benzoxazine oxazolidinone compounds represented by the following general formula (I), preparation methods and uses thereof in preparing medicament for treating infectious diseases, especially infectious diseases caused by multi-drug resistant bacteria, are disclosed.

The present invention is directed to use of cannabidiol and compositions thereof as an anti-bacterial agent against multi-drug resistant bacteria such as Pseudomonas aeruginosa.

The invention discloses a compound capable of effectively inhibiting or killing bacterial microorganisms. The compound has a structural general formula shown as the formula I (please see the formula in the description). Pharmacodynamic experiments prove that the compound can effectively inhibit or kill the broad-spectrum and multi-drug resistant staphylococcus aureus, streptococcus pneumoniae and staphylococcus aureus and is expected to be developed into a novel effective antibacterial drug with new targets.

The invention discloses a cyclic peptide resistant to multi-drug resistant bacteria. The cyclic peptide resistant to the multi-drug resistant bacteria is characterized in that the amino acid sequenceis any of CPeptide-A, CPeptide-B, CPeptide-C and CPeptide-D, and the antibacterial cyclic peptide is obtained through cyclization of amido bonds formed by amino groups and carboxy groups of head and tail amino acids of any of the amino acid sequence. The four novel artificially designed cationic antibacterial peptides can be synthesized by adopting an Fmoc solid-phase chemical method, the operability is strong, and the cost is low. The cationic antibacterial peptides have broad spectrum killing activity against multidrug-resistant acinetobacter baumannii, have stronger bactericidal activity than natural antimicrobial peptides, and have no toxic effect on animal and plant cells.

The invention discloses an NDM-1 locked nucleic acid probe modified electrode as well as a preparation method and application thereof. Specifically, a locked nucleic acid modified probe is designed, which immobilized on the surface of an electrode to serve as a specific probe, wherein the 5' end of the locked nucleic acid probe is modified with a sulfydryl and then the sulfydryl can be immobilized on the surface of the electrode by virtue of chemical bonding of an Au-S bond; the locked nucleic acid probe is mutually complementary with partial sequence of a target gene. The NDM-1 locked nucleic acid probe modified electrode provides a brand new thought and a detection method for the detection of multiple drug-resistant bacteria.

The invention provides a method and system for synchronously detecting the number of cases infected with multi-drug-resistant bacteria based on MapReduce and big data management. Based on the MapReduce framework, the parallel computing capability of a machine in a distributed system is utilized, the task of calculating the number of cases infected with multi-drug-resistant bacteria in a hospital in millions and tens of millions of inpatients beyond the memory and storage limit of a server is divided into tens of millions and billions of small tasks, the small tasks are simultaneously executedon a plurality of machines, and intermediate output results of the small tasks are summarized to generate a final result. According to the invention, massive parallel computing can be carried out on big data of millions, tens of millions and hundred millions of inpatients according to various calibers such as provincial and municipal areas, hospital levels, hospital beds, comprehensive and specialized departments, publicity and camp, all types of infections related to the multi-drug-resistant bacteria are managed, accurate statistics of the number of cases infected with the multi-drug-resistant bacteria in the hospital is achieved, hospital infection is integrally evaluated, and overall prevention, control and management of hospital infection of the multi-drug-resistant bacteria are achieved.

The invention provides a Chinese medicinal external cleaning agent for treating infectious wounds caused by multi-drug-resistant bacteria, which relates to the field of Chinese medicinal compositionsand comprises the following raw materials in parts by weight: rhubarb 12-16 parts, Angelica 6-9 parts, astragalus root 7-10 parts, pearl powder 8-14 parts, calamine 7-11 parts, bezoar 7-10 parts, pseudo-ginseng 5-10 parts, nail beads 3-10 parts, Phellodendron amurense 7-10 parts, dragon's blood 5-12 parts, blood charcoal 9-14 parts, honeysuckle 11-14 parts, and rhizoma Polygoni Cuspidati 3-9 parts, Patrinia villosa 2-10 parts, water extract of milk perfume 5-9 parts. The external cleaning agent prepared by the invention can accelerate the recovery speed of the infectious wound, help the granulation tissue to grow and promote the wound healing, and assist the patient to recover as soon as possible.

The invention discloses an aggregation infection route monitoring method, device and equipment and a storage medium, and the method comprises the steps: querying the identity information of a user who initiates an infection route locking request, and determining the user authority of the user according to the identity information, inquiring hospitalization process information, transfer information, drug-resistant bacteria inspection information, bed distribution information and medical staff nursing information of the patient pointed by the infection route locking request; determining a zero case; and determining and outputting a propagation relation path according to the bacteria detection date and the occurrence time of the time-space relationship by combining all the multi-drug-resistant bacteria detection cases with the time-space relationship according to the zero case. The method, the device, the equipment and the storage medium have the beneficial effects that the zero case is determined according to the hospitalization process information, the transfer information, the drug-resistant bacteria test information, the bed distribution information and the nursing information of the medical staff of the patient, so that the hospitalization aggregation event infection route is quickly locked.

The invention relates to an application of bronopol and an analogue thereof in the preparation of antibacterial drugs, and belongs to the medicine filed. The chemical name of antibacterial is 2-bromo-2-nitro-1,3-propylene glycol, and the chemical name of the analogue of bronopol is 2,2-dibromo-2-nitroethanol. Bronopol and analogue thereof have a very good inhibition activity on bacteria, and drug resistant bacteria, especially multi-drug resistant bacteria, and can be used to treat a plurality of common bacterial infections of livestock and poultry.

The invention belongs to the technical field of antibacterial materials, and discloses mFGA-TC composite nano hydrogel as well as a preparation method and application thereof. Quaternary ammonium salt chitosan and tannic acid are cross-linked to form a matrix, and an mFe3O4-GO-AIBI composite nano material with a core-shell structure is uniformly dispersed. The preparation method comprises the following steps: synthesizing hollow ferroferric oxide nanoparticles through a solvothermal method, coating polyethyleneimine modified graphene oxide by utilizing electrostatic interaction, and loading an azo initiator AIBI; and mixing with quaternary ammonium salt chitosan and a tannic acid solution, and carrying out cross-linking molding. The photothermal effect of ferroferric oxide, the physical and chemical damage capability of graphene oxide and the free radical killing effect generated by AIBI are combined and are integrated with biocompatible hydrogel, and photothermal / photodynamic synergistic efficient antibiosis is achieved. The hydrogel has a remarkable inhibition effect on multi-drug-resistant bacteria, can effectively promote wound healing, and has a wide application prospect in the field of bacterial infectious wound dressings.

The application discloses application of gynostemma pentaphyllum saponin H combined with azole drugs in preparation of antifungal drugs and the antifungal drugs, and relates to the technical field of antifungal drugs. It is found through systematic in-vitro drug sensitivity test that natural product gynostemma pentaphyllum saponin H combined with specific azole antifungal drugs (especially posaconazole POS) can produce significant synergistic antifungal effect, especially for clinical thorny aspergillus, candida, new cryptococcus and dark fungi. The combination strategy can significantly reduce the minimum inhibitory concentration of azole drugs, reverse drug resistance, and is effective for multi-drug resistant strains (such as candida auris). The application provides an efficient and low-toxicity new combination drug scheme for overcoming the increasingly serious fungal drug resistance problem.

The invention relates to the field of pharmaceutical chemistry, in particular to a five-membered heterocyclic dicarbonyl derivative (I) and application thereof on multi-drug resistant bacteria. Pharmacology experiments prove that the multi-drug resistant bacteria can be well inhibited through combined use of the compound in the invention and antibiotic.

The invention discloses a traditional Chinese medicinal external lotion for treating infective wounds caused by multi-drug resistant bacteria. According to traditional Chinese medicine, treatment based on syndrome differentiation is conducted in accordance with different symptoms of deficiency and excess, cold and heat, blood stasis and edema for the pathogenesis causing the infective wounds due to multi-drug resistant bacteria. The external lotion disclosed by the invention is prepared from the following traditional Chinese medicines: indian stringbush root, yellow bedstraw herb, Chinese crinum leaves, breeders gladiolus corm, wedelia chinensis, pyrolusite, circaeashape loosestrife herb, gelsmium elegans, kerr treebine keaf, euphorbia antiquorum, beautiful galangal seeds and herba eupatorii. Upon clinical tests, the total effective rate reaches 95%; and the external lotion is free from cases of cross infection and is relatively good in curative effect.

The invention belongs to the technical field of biological medicines, and discloses an artificially synthesized antibacterial peptide, a derivative thereof and an application of the artificially synthesized antibacterial peptide in resisting escherichia coli. The antibacterial peptide provided by the invention has a strong inhibition effect on escherichia coli and comprises multiple drug-resistant strains. Experiments show that the antibacterial peptide has high in-vitro antibacterial activity, excellent thermal stability, acid-base stability and no hemolytic activity, has no obvious toxicity to mammalian cells, and shows a remarkable treatment effect in a chicken escherichia coli infection model. The invention provides a novel antibacterial preparation for coping with escherichia coli, especially infection of drug-resistant strains.

Disclosed is pollution-free functional water with deodorization activity and sterilization activity against multi-drug resistant bacteria. In the present invention, the functional water is prepared by treating a solution which contains mixture of pulverized molasses, soybean and bamboo through decomposition tank, a first precipitation tank, bio-tank, a second precipitation tank and filter. Also, disclosed is a method for preparing the functional water.